Corbus Pharmaceuticals (CRBP) Stock Price, News & Analysis

Company Overview

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Key Stats

• Today's Range: $9.35 to $9.98
• 50-Day Range: $6.90 to $10.47
• 52-Week Range: $4.64 to $61.72
• Volume: 87,032 shs
• Average Volume: 101,593 shs
• Market Capitalization: $114.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $49.00
• Consensus Rating: Buy

Corbus Pharmaceuticals Stock Analysis - MarketRank™

Corbus Pharmaceuticals scored higher than 84% of companies evaluated by MarketBeat, and ranked 174th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Corbus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 9 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Corbus Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Corbus Pharmaceuticals are expected to decrease in the coming year, from ($4.23) to ($6.29) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Corbus Pharmaceuticals is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Corbus Pharmaceuticals is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Corbus Pharmaceuticals has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.58% of the float of Corbus Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Corbus Pharmaceuticals has a short interest ratio ("days to cover") of 8.2.

Change versus previous month

Short interest in Corbus Pharmaceuticals has recently decreased by 9.49%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Corbus Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Corbus Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.65

Percentage of Shares Shorted

11.58% of the float of Corbus Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Corbus Pharmaceuticals has a short interest ratio ("days to cover") of 8.2.

Change versus previous month

Short interest in Corbus Pharmaceuticals has recently decreased by 9.49%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.00

News Sentiment

Corbus Pharmaceuticals has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Corbus Pharmaceuticals this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for CRBP on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

7 people have added Corbus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Corbus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,547.00 in company stock.

Percentage Held by Insiders

Only 3.60% of the stock of Corbus Pharmaceuticals is held by insiders.

Percentage Held by Institutions

64.64% of the stock of Corbus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CRBP Stock Analysis - Frequently Asked Questions

How have CRBP shares performed this year?

Corbus Pharmaceuticals' stock was trading at $11.80 at the beginning of 2025. Since then, CRBP shares have decreased by 20.6% and is now trading at $9.37.

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) released its quarterly earnings results on Tuesday, August, 5th. The biopharmaceutical company reported ($1.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.55) by $0.11.

Who are Corbus Pharmaceuticals' major shareholders?

Corbus Pharmaceuticals' top institutional shareholders include Exome Asset Management LLC (2.26%), Armistice Capital LLC (1.57%), Atle Fund Management AB (1.43%) and Geode Capital Management LLC (1.09%). Insiders that own company stock include Yuval Cohen, Sean F Moran, Anne Altmeyer and John Kenneth Jenkins.
View institutional ownership trends.

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Corbus Pharmaceuticals investors own include Visa (V), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Alibaba Group (BABA) and Pfizer (PFE).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 8/30/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CRBP
• CIK: 1595097
• Web: www.corbuspharma.com
• Phone: (617) 963-0100
• Fax: 617-663-6085
• Employees: 40
• Year Founded: 2009

Price Target and Rating

• Average Price Target for Corbus Pharmaceuticals: $49.00
• High Price Target: $74.00
• Low Price Target: $28.00
• Potential Upside/Downside: +422.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.10
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$40.21 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -43.65%
• Return on Assets: -39.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.21
• Quick Ratio: 9.21

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.06 per share
• Price / Book: 1.03

Miscellaneous

• Outstanding Shares: 12,260,000
• Free Float: 11,814,000
• Market Cap: $114.88 million
• Optionable: Optionable
• Beta: 3.20